Skip to main content

Table 1 Immunogenicity sample collection schedule

From: Assessment of clinical immunogenicity of inotuzumab ozogamicin in patients with non-Hodgkin lymphoma and acute lymphoblastic leukemia

Cycle 1 (Predose)a Cycle 2 Cycle 3 Cycle 4 Cycle 5 Cycle 6 Cycle 7 EOT
Patients with relapsed or refractory ALL who received single-agent InOb
x    x     x
x x x x x x   x
Patients with relapsed or refractory NHL who received single-agent InOc
x x x x x   x x
x x x x x   x x
x   x      x
Patients with relapsed or refractory NHL who received InO plus rituximabc
  x x x x   x x
  x x x x   x x
x        
x    x     x
x x x x x x   x
Patients with relapsed or refractory NHL who received InO plus rituximab plus chemotherapyc
x    x     x
  1. Samples taken predose for respective treatment cycles
  2. ALL acute lymphoblastic leukemia, ECL electrochemiluminescence, ELISA enzyme-linked immunosorbent assay, EOT end of treatment, InO inotuzumab ozogamicin, NHL non-Hodgkin lymphoma
  3. aBefore first InO treatment. May have been omitted if sample taken at screening
  4. bECL assay
  5. cELISA